Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P

Original languageEnglish
Pages (from-to)210-220
Number of pages11
JournalInternational Journal of Clinical Oncology
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Hepacivirus
Interferons
Hepatocellular Carcinoma
Recurrence
Survival Rate
Propensity Score
Survival
Selection Bias
Virus Diseases
Therapeutics
Causality
Control Groups

Keywords

  • Hepatitis C virus
  • Hepatocellular carcinoma
  • PEG-IFN
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. / Hagihara, Hiroaki; Nouso, Kazuhiro; Kobayashi, Yoshiyuki; Iwasaki, Yoshiaki; Nakamura, Shinichiro; Kuwaki, Kenji; Toshimori, Junichi; Miyatake, Hirokazu; Ohnishi, Hideki; Shiraha, Hidenori; Yamamoto, Kazuhide.

In: International Journal of Clinical Oncology, Vol. 16, No. 3, 06.2011, p. 210-220.

Research output: Contribution to journalArticle

Hagihara, Hiroaki ; Nouso, Kazuhiro ; Kobayashi, Yoshiyuki ; Iwasaki, Yoshiaki ; Nakamura, Shinichiro ; Kuwaki, Kenji ; Toshimori, Junichi ; Miyatake, Hirokazu ; Ohnishi, Hideki ; Shiraha, Hidenori ; Yamamoto, Kazuhide. / Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. In: International Journal of Clinical Oncology. 2011 ; Vol. 16, No. 3. pp. 210-220.
@article{8c84e268ecf64c41ab3d2cb70d2af62b,
title = "Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma",
abstract = "Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91{\%}) was significantly higher than that in the non-IFN group (56{\%}; P",
keywords = "Hepatitis C virus, Hepatocellular carcinoma, PEG-IFN, Recurrence, Survival",
author = "Hiroaki Hagihara and Kazuhiro Nouso and Yoshiyuki Kobayashi and Yoshiaki Iwasaki and Shinichiro Nakamura and Kenji Kuwaki and Junichi Toshimori and Hirokazu Miyatake and Hideki Ohnishi and Hidenori Shiraha and Kazuhide Yamamoto",
year = "2011",
month = "6",
doi = "10.1007/s10147-010-0150-x",
language = "English",
volume = "16",
pages = "210--220",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

AU - Hagihara, Hiroaki

AU - Nouso, Kazuhiro

AU - Kobayashi, Yoshiyuki

AU - Iwasaki, Yoshiaki

AU - Nakamura, Shinichiro

AU - Kuwaki, Kenji

AU - Toshimori, Junichi

AU - Miyatake, Hirokazu

AU - Ohnishi, Hideki

AU - Shiraha, Hidenori

AU - Yamamoto, Kazuhide

PY - 2011/6

Y1 - 2011/6

N2 - Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P

AB - Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - PEG-IFN

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=80051767247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051767247&partnerID=8YFLogxK

U2 - 10.1007/s10147-010-0150-x

DO - 10.1007/s10147-010-0150-x

M3 - Article

C2 - 21152943

AN - SCOPUS:80051767247

VL - 16

SP - 210

EP - 220

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 3

ER -